The inhibition of protein C anticoagulant activity by anti-β2-glycoprotein I (β2GPI) antibodies isolated from patients with antiphospholipid syndrome by chromatography methods

References

• Bowie EJW, Thompson JH, Pascuzzi CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulant. J Lab Clin Med 1963;62:416–21.
   Google Scholar
• Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the "lupus"-type circulating anticoagulant. Ann Intern Med 1980;92:156–59.
   Google Scholar
• Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GRV. Thrombosis in systemic lupus erythematosus: striking asso-ciation with presence of circulating lupus anticoagulant. Br Med J 1983;87:1021–3.
   Google Scholar
• McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: p2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120–4.
   PubMed Web of Science ®Google Scholar
• Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJC, et al. Anticardiolipin antibodies (ACA) are directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544–7.
   Google Scholar
• Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoim-mune disease. Lancet 1990;336:177–8.
   Google Scholar
• Heimburger N, Heide K, Haupt H, Schultze HE. Bausteinanalysen von Human Serum Protein. Clin Chim Acta 1964;10:293–302.
   PubMedGoogle Scholar
• Nimpf J, Wurm H, Kostner GM. Interaction of p2 glycoprotein-I with human blood platelets: influence upon ADP-induced aggrega-tion. Thromb Haemostasis 1985;54: 397–401.
   Google Scholar
• Schousboe I. p2 glycoprotein I: a plasma inhibitor of the contact activation of intrinsic coagulation pathway. Blood 1985;66:1086–91.
   PubMed Web of Science ®Google Scholar
• NimpfJ, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, et al. Prothrombinase activity of human platelets is inhibited by p2 glycoprotein-I. Biochim Biophys Acta 1986;884:142–9.
   PubMedGoogle Scholar
• Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. p2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemostasis 1996; 75:49–55.
   Google Scholar
• Esmon CT, Owen WG. Identification of an endothelial cell cofac-tor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981;78:2249–52.
   PubMed Web of Science ®Google Scholar
• Stenflo J. Structure and function of protein C. Semin Thromb Hemost 1984;10:109–21.
   PubMedGoogle Scholar
• Galli M, Ruggeri L, Barbui T. Differential effects of anti-132-glyco-protein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998;91: 1999–2004.
   Google Scholar
• Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K, et al. 32-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999; 42:167–74.
   PubMedGoogle Scholar
• Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, et al. Heterogeneity anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992;148:3885–91.
   PubMed Web of Science ®Google Scholar
• McNeil HP, Krilis SA, Chesterman CN. Purification of antiphospholipid antibodies using a new affinity method. Thromb Res 1988;52:641–8.
   Google Scholar
• Brandt JT. Assay for phospholipid-dependent formation of throm-bin and factor Xa: a potential method for quantifying lupus antico-agulant activity. Thromb Haemostasis 1991;66:453–8.
   PubMedGoogle Scholar
• Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Moclouf J, et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells: inhibition of thrombomodulin-dependent protein C activation. Thromb Haemostasis 1988;60:54–8.
   PubMed Web of Science ®Google Scholar
• Keeling DM, Wilson AJG, Mackie IJ, Isenberg DA, Machin SJ. Role of 32-glycoprotein I and anti-phospholipid antibodies in acti-vation of protein C in vitro. J Clin Pathol 1993;46: 908–11.
   Google Scholar
• Fanelli A, Bergamini C, Rapi S, Caldini A, Spinelli A, Bugguani A, 27. et al. Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome. Correlation with thrombo-cytopenia and anticardiolipin antibodies. Lupus 1997;6: 261–7.
   Google Scholar
• Reverter JC, Tassies D, Font J, Khamashta MA, Ichikawa K, 28. Cervera R, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998;41:1420–7.
   Google Scholar
• Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, 29. Ichikawa K, et al. Endothelial cells as target for antiphospholipid antibodies: human polyclonal and monoclonal anti-132-glycoprotein I antibodies react in vitro with endothelial cells through adherent 30. 32-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997;40: 551–61.
   Google Scholar
• George J, Blank M, Levy Y, Meroni P, Damianovich M, Tincani A, et al. Differential effects of anti-132-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental 31. antiphospholipid syndrome. Circulation 1998;97:900–6.
   PubMed Web of Science ®Google Scholar
• Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994;83:2532-40.32.
   Google Scholar
• Ames PR, Tommasino C, Iannaccone L, Briltante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies: a crucial role for acquired free protein S deficiency. Thromb Haemostasis 1996;76:190–4.
   PubMedGoogle Scholar
• Astumi T, Khamashta MA, Andujar C, Leandro MJ, Amengual O, Ames PR, et al. Elevated plasma lipoprotein (a) level and its association with impaired fibrinolysis in patients with antipho-spholipid syndrome. J Ftheumatol 1998;25:69–73.
   Google Scholar
• Rand JH, Wu X, Andree HAM, Ross JB, Rusinova E, Gascon-Lema MG, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholip-ids: a "lupus procoagulant" phenomenon. Blood 1998;92: 1652–60.
   PubMed Web of Science ®Google Scholar
• Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of acti-vated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990;76:101–7.
   PubMed Web of Science ®Google Scholar
• Oosting JD, Derksen FtHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism. Blood 1993;81:2618–25.
   Google Scholar
• POtzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Miller-Berghaus G. Acquired protein C dysfunction but not de-creased activity of thrombomodulin is a possible marker of throm-bophilia in patients with lupus anticoagulant. J Lab Chin Med 1995;125:56–65.
   Google Scholar
• Merrill JT, Zhang HW, Shen C, Butman BT, Jeffries EP, Lahita RG, et al. Enhancement of protein S anticoagulant function by p2-glycoprotein I, a major target antigen of antiphospholipid anti-bodies: 32-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemostasis 1999;81:748–57.
   PubMedGoogle Scholar